A new analysis in the British Journal of Cancer links the timing of immune checkpoint inhibitor dosing to overall survival in advanced cancer, according to results from a large, single-center cohort. Rather than asking only whether immunotherapy works, the study examines how when therapy is administered can shape outcomes—an approach that could influence real-world scheduling, sequencing with other treatments, and protocol design. The findings add to growing evidence that immunotherapy performance may depend on more than drug selection, making timing a variable under active investigation as oncology centers standardize care pathways.